Ectin Research AB (XSAT:ECTIN B) ROCE % : -242.25% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ectin Research AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -242.25%.

Ectin Research AB ROCE % Historical Data

The historical data trend for Ectin Research AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB ROCE % Chart

Ectin Research AB Annual Data

Trend

Aug19

Aug20

Dec22

Dec23

ROCE %

-4.98

-11.36

-83.03

-127.00

Ectin Research AB Quarterly Data
	Aug19	Aug20	Mar21	Sep21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial								-49.95	-28.22	-50.18	-423.79	-242.25

Ectin Research AB ROCE % Calculation

Ectin Research AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-17.2	/	( ( (23.756 - 1.598)	+	(6.428 - 1.499) )	/ 2 )
	=	-17.2	/	( (22.158	+	4.929)	/ 2 )
	=	-17.2	/	13.5435
	=	-127.00 %

Ectin Research AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-9.156	/	( ( (6.428 - 1.499)	+	(4.418 - 1.788) )	/ 2 )
	=	-9.156	/	( ( 4.929	+	2.63 )	/ 2 )
	=	-9.156	/	3.7795
	=	-242.25 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Ectin Research AB (XSAT:ECTIN B) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ectin Research AB ROCE % Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ectin Research AB (XSAT:ECTIN B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.ectinresearch.com

Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines